A recent editorial in the Journal of Clinical Endocrinology and Metabolism (JCEM) has indicated that "Effective January 1, 2015, manuscripts reporting sex steroid assays as important end-points must use MS-based assays." They expanded by stating "It is anticipated that this requirement for MS-based assays will extend to adrenal steroids and vitamin D in the near future". While this is temporarily limited to manuscripts submitted to the JCEM it is an attitude that will continue to advance in the research community.
With the purchase of our Agilent LC/MS/MS technologies, Heartland Assays is in an excellent position to meet this need for the Vitamin D community. Thus far we have validated assays for Vitamin D2, Vitamin D3, 3-epi-25(OH)D3, 25(OH)D2, 25(OH)D3, 24,25(OH)2D2 and 24,25(OH)2D3. We will soon have assays for 1,25(OH)2D2, 1,25(OH)2D3, 1,24,25(OH)3D2 and 1,24,25(OH)3D3.
To read the full editorial piece click here.